Crown Bioscience and Data Sciences International (DSI) announced the successful development of an enhanced method for preclinical obesity and type 2 diabetes studies in partnership. Crown Bioscience’s clinically relevant models and DSI’s HD-XG implantable glucose device combine to create a superior approach to preclinical metabolic disease research.
Recently published work in the Journal of Endocrinological Investigation and Nature’s Scientific Reports demonstrates the advantages of a new method using DSI’s HD-XG implantable glucose device and Crown Bioscience’s models of spontaneous and diet-induced diabetes. The HD-XG device allows for continuous, long-term measurement of blood glucose, temperature, and locomotor activity and eliminates stress inducing blood sampling that can inadvertently skew glucose levels and cause blood volume to decline. The published data support use of this superior method to thoroughly imonitor glucose levels in Crown Bioscience’s clinically relevant models of human metabolic disease.
“We are excited to provide researchers with this powerful new method to advance preclinical obesity and diabetes programs,” said Jim Wang, M.D., Crown Bioscience’s Senior Vice President Cardiovascular and Metabolic Diseases (CVMD) Research, “By leveraging Crown Bioscience’s models to recapitulate human metabolic disease and DSI’s HD-XG device to reliably investigate changes in blood glucose, researchers can gain unpresented insight into the pathophysiology of metabolic diseases and the pharmacology of related investigational compounds.”